The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats
Introduction
The cyclooxygenase pathway leads to the production of prostaglandins, which possess both pro- and antiinflammatory properties. There are two known isoforms of cyclooxygenase, namely, cyclooxygenase-1, which is a constitutive enzyme. It is present in nearly all tissues and appears to be critical in maintaining mucosal defenses and plays a key role in mediating platelet aggregation (Carty et al., 2000, Gerd and Werner, 2001). On the other hand, cyclooxygenase-2 is the inducible form of the enzyme, which is expressed in response to the stimulation of inflammatory cells, such as synoviocytes, macrophages and endothelial cells. Stimulants of this isozyme include the proinflammatory cytokines, prostaglandins and tumor necrosis factor-α (Balfour, 1994, Newberry et al., 1999).
Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the generation of prostanoids, but their effects vary in different tissues and organs. The function of the two cyclooxygenase isoforms, cyclooxygenase-1 and cyclooxygenase-2, in maintaining mucosal homeostasis and modulating inflammation in the digestive tract remains uncertain. The generation of prostanoids in the colonic mucosa is increased in both experimentally induced colitis and in inflammatory bowel disease and correlates well with disease activity (Salvatore et al., 2001, Kruidenier and Verspaget, 2002).
Indomethacin, a conventional NSAID, inhibits both cyclooxygenase isoforms, which are induced by acute and chronic enterocolitis in genetically susceptible rats (Yamada et al., 1993). This effect is attributed to the inhibition of the synthesis of prostaglandins in the gastric mucosa. These prostaglandins are known to possess cytoprotective properties (Wallace et al., 1992). The relative contribution of cyclooxygenase-1 and cyclooxygenase-2 isoforms to the biological actions of prostaglandins in the gastrointestinal mucosa is less clear. Several investigators advocated the hypothesis that the inducible form of cyclooxygenase is the source for the proinflammatory prostaglandins released during mucosal injury. In contrast, cyclooxygenase-1 regulates gastrointestinal homeostasis through the synthesis of cytoprotective prostaglandins (Masferrer et al., 1996).
In mice, cyclooxygenase-1 has been reported to play a protective role against mucosal injury of the small intestine (Cohn et al., 1997) and the colon (Tessner et al., 1998). On the other hand, cyclooxygenase-2 expression is induced during inflammation (Singer et al., 1998), and its expression is inhibited by the release of endogenous glucocorticoids (O'Bannion et al., 1991, Karmeli et al., 2000). Based on these observations, some researchers have attributed the antiinflammatory action of NSAIDs to the inhibition of cyclooxygenase-2 and their harmful effects to the inhibition of cyclooxygenase-1 (Eliakim et al., 1992, Xie et al., 1992). This association between cyclooxygenase-2 and the inflammatory events led to the development of selective cyclooxygenase-2 inhibitors, which are expected to display systemic antiinflammatory properties without the anticipated gastrointestinal toxicity. Recently, clinical trials in patients with osteoarthritis documented the safety of the selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on gastric mucosa as compared to the traditional NSAIDs (Goldstein et al., 2000, Martin et al., 2003).
The effect of NSAIDs in the possible modulation of colon inflammation is still controversial and remains uncertain. NSAIDs may be associated with exacerbation of ulcerative colitis and Crohn's disease (Fabia et al., 1993, Felder et al., 2000). Many patients with ulcerative colitis and Crohn's disease are advised to avoid the use of NSAIDs to prevent disease exacerbation (Bonner, 2001). However, the data in this regard have been inconsistent. There are some reports that showed no association between the use of NSAIDs and exacerbation of the underlying inflammatory bowel disease (Dominitz and Boyko, 2000, Mahadevan et al., 2001). This relative contraindication is a problem for those patients who suffer from irritable bowel disease-associated inflammatory arthropathies.
Animal models are used extensively to study the pathogenesis and pathophysiology of inflammatory bowel disease and to evaluate therapies (Morris et al., 1989, Elson et al., 1995, Wallace and Tigley, 1995). Acetic-acid-induced colitis in rats resembles human ulcerative colitis in histology, eicosanoid production and excessive oxygen-derived free radicals release by inflamed mucosa (Millar et al., 1996). Therefore, this study was undertaken to evaluate and compare the effects of two selective cyclooxygenase-2 inhibitors, namely, celecoxib and rofecoxib, on the extent and severity of colitis induced by acetic acid in rats, using macroscopic, microscopic and biochemical studies.
Section snippets
Materials
Celecoxib and rofecoxib were a generous gift from Searle, USA, and Merck, USA, respectively. 5,5-Dithiobis-2-nitrobenzoic acid (DTNB), reduced glutathione (GSH), adenosine diphosphate, platelet-activating factor (PAF) and agents for myeloperoxidase (MPO) assay were purchased from Sigma, St. Louis, MO, USA. Histamine diphosphate monohydrate was purchased from BDH, U.K. l-Arginine and l-citrulline were from Amersham, Bucks, UK. All other chemicals used were of analytical grade.
Animals
Forty male Wistar
Macroscopic
Twenty-four hours after the administration of 3% acetic acid into the colon, macroscopic inspection showed evidence of damage, namely, the presence of mucosal congestion, extensive disruption and linear and deep haemorrhagic ulceration (Fig. 1). In this experimental group, there was evidence of haemorrhagic diarrhoea and weight loss (Fig. 2).
Treatment of rats with either rofecoxib or celecoxib significantly attenuated the extent and severity of the colonic injury and reduced the score of the
Discussion
The present study showed that treatment with the cyclooxygenase-2 inhibitors rofecoxib and celecoxib reduced the inflammation and the damage to the colon, induced by acetic acid, as verified by our macroscopic, histological and biochemical findings.
The results of the present study clearly demonstrated that celecoxib and rofecoxib exert a significant attenuation of the extent and severity of the histological signs of cell damage. These results are in agreement with Martin et al. (2003), who
Acknowledgements
The authors wish to express their gratitude to Ms. Elsa Lina Aureus for her technical assistance and typing of the manuscript.
References (50)
- et al.
Lipoxygenase products of arachidonic acid modulate biosynthesis of platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by human neutrophils via phospholipase A2
J. Biol. Chem.
(1985) - et al.
Measurements of cutaneous inflammation: estimation of neutrophil content with an enzyme marker
J. Invest. Dermatol.
(1982) Exacerbation of inflammatory bowel disease with use of celecoxib
Am. J. Gastroenterol.
(2001)Current roles of nitric oxide in gastrointestinal disorders
J. Physiol. (Paris)
(2001)- et al.
Celecoxib, a selective cyclooxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulphonic acid in rats
Eur. J. Pharmacol.
(2001) - et al.
Experimental models of inflammatory bowel disease
Gastroenterologist
(1995) - et al.
Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study
Am. J. Gastroenterol.
(2000) - et al.
Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel Cox-2 inhibitor
Am. J. Gastroenterol.
(2000) - et al.
Metabolism of trinitrobenzene sulphonic acid by the rat colon produces reactive oxygen species
Gastroenterology
(1991) - et al.
Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats
Gastroenterology
(1999)
Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats
Eur. J. Pharmacol.
Histamine in the pig determination distribution, release and pharmacological actions
Eur. J. Pharmacol.
Thymoquinone protects against experimental colitis in rats
Toxicol. Lett.
Potential protective effects of sucralfate against acetic-induced colitis in rats
JDP
Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract
Gastroenterol. Clin. North Am.
Hapten-induced model of chronic ulceration in the rat colon
Gastroenterologist
Cyclooxygenase-2 is induced in colonic epithelial cells in inflammatory bowel disease
Gastroenterology
Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice
Gastroenterology
Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis
Gastroenterology
Cytokines in intestinal inflammation: pathophysiological and clinical considerations
Gastroenterology
Involvement of histamine in a rat model of inflammatory bowel disease
Gastroenterology
Measurement of in-vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper
Gut
Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1
J. Clin. Invest.
Association between analgesic use and inflammatory bowel disease flares. A retrospective cohort study
Gastroenterology
Role of platelet activating factor in ulcerative colitis
Gastroenterology
Cited by (45)
Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate
2019, International Journal of PharmaceuticsCitation Excerpt :NSAIDs inhibit cyclooxygenase (COX), the enzyme family responsible for the translation of arachidonic acid to prostaglandins (Steinbach et al., 2000). COX exists in two isoforms, COX-1, which plays a cytoprotective role (El-Medany et al., 2005), and COX-2, which induces inflammatory stimuli (Radi and Khan, 2006). As traditional NSAIDs are nonselective COX inhibitors, mucosal prostaglandin synthesis and gastric mucosal cytoprotection are disrupted, severe gastrointestinal side effects (Kim et al., 2013; Silverstein et al., 2000; Vane and Botting, 1987) are common (Warner et al., 1999).
Colonic epithelial mTORC1 promotes ulcerative colitis through COX-2-mediated Th17 responses
2018, Mucosal ImmunologyAmeliorative effect of chromium-D-phenylalanine complex on indomethacin-induced inflammatory bowel disease in rats
2017, Biomedicine and PharmacotherapyCo-delivery of multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance
2017, Colloids and Surfaces B: BiointerfacesCitation Excerpt :No unambiguous conclusion can be drawn from the present results. For example, it was reported that the oral administration of celecoxib could recover the decreased GSH level in N-nitrosobis ((2-oxopropyl)amine)-treated hamsters [35] and the decreased GSH level induced by acetic acid in the colonic tissue of rats [36]. Previous study showed that celecoxib could reverse the decrease of GSH induced by H2O2 in HeLa/bcl-2 cells [37].